1. Cantón R, Coque TM (2006) The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 9(5):466–475
2. Pitout JD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8(3):159–166
3. Ramphal R, Ambrose PG (2006) Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 42(Suppl 4):S164–S172
4. Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H (1995) Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother 39(10):2269–2275
5. Yamaguchi K, Ishii Y, Iwata M, Yoshida H, Satoh T, Watanabe N, Uehara N, Murakami M, Takahashi A, Yasujima M, Kasai T, Itoh K, Shibuya Y, Suwabe A, Obata R, Kanno H, Kubo S, Kaku M, Kanemitsu K, Maesaki S, Hashikita G, Igari J, Oguri T, Aihara M, Kinoshita S, Okada J, Tazawa Y, Taminato T, Negayama K, Nakashima H, Takemura H, Murase M, Miyamoto H, Horii T, Kusano N, Mihara E, Baba H, Ishigo S, Kambe M, Itaha H, Fujita N, Komori T, Ono J, Yoshimura H, Ichiyama S, Maeda S, Hirakata Y, Matsuda J, Yamanaka K, Murata Y, Saikawa T, Hiramatsu K (2004) Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002. Jpn J Antibiot 57(1):70–104